Logo image of MDGL

MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Fundamental Analysis

NASDAQ:MDGL - Nasdaq - US5588681057 - Common Stock - Currency: USD

315.48  -12.22 (-3.73%)

After market: 315.48 0 (0%)

Fundamental Rating

3

Overall MDGL gets a fundamental rating of 3 out of 10. We evaluated MDGL against 567 industry peers in the Biotechnology industry. While MDGL seems to be doing ok healthwise, there are quite some concerns on its profitability. MDGL is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MDGL had negative earnings in the past year.
In the past year MDGL has reported a negative cash flow from operations.
MDGL had negative earnings in each of the past 5 years.
MDGL had a negative operating cash flow in each of the past 5 years.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

With a Return On Assets value of -48.33%, MDGL perfoms like the industry average, outperforming 48.06% of the companies in the same industry.
The Return On Equity of MDGL (-66.74%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -48.33%
ROE -66.74%
ROIC N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K

1.3 Margins

MDGL's Gross Margin of 226.39% is amongst the best of the industry. MDGL outperforms 99.65% of its industry peers.
MDGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 226.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

5

2. Health

2.1 Basic Checks

MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MDGL has been increased compared to 1 year ago.
Compared to 5 years ago, MDGL has more shares outstanding
MDGL has a better debt/assets ratio than last year.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 11.84 indicates that MDGL is not in any danger for bankruptcy at the moment.
MDGL has a Altman-Z score of 11.84. This is amongst the best in the industry. MDGL outperforms 89.93% of its industry peers.
MDGL has a Debt/Equity ratio of 0.15. This is a healthy value indicating a solid balance between debt and equity.
MDGL has a worse Debt to Equity ratio (0.15) than 68.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Altman-Z 11.84
ROIC/WACCN/A
WACC10.02%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M

2.3 Liquidity

A Current Ratio of 5.98 indicates that MDGL has no problem at all paying its short term obligations.
MDGL has a better Current ratio (5.98) than 63.43% of its industry peers.
A Quick Ratio of 5.93 indicates that MDGL has no problem at all paying its short term obligations.
MDGL's Quick ratio of 5.93 is fine compared to the rest of the industry. MDGL outperforms 63.96% of its industry peers.
Industry RankSector Rank
Current Ratio 5.98
Quick Ratio 5.93
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.83% over the past year.
EPS 1Y (TTM)21.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MDGL will show a very strong growth in Earnings Per Share. The EPS will grow by 42.47% on average per year.
Based on estimates for the next years, MDGL will show a very strong growth in Revenue. The Revenue will grow by 83.57% on average per year.
EPS Next Y41.51%
EPS Next 2Y43.5%
EPS Next 3Y45.37%
EPS Next 5Y42.47%
Revenue Next Year235.79%
Revenue Next 2Y142.24%
Revenue Next 3Y116.01%
Revenue Next 5Y83.57%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 50 100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MDGL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 240.92, the valuation of MDGL can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MDGL indicates a rather cheap valuation: MDGL is cheaper than 89.40% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of MDGL to the average of the S&P500 Index (20.86), we can say MDGL is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 240.92
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
MDGL's earnings are expected to grow with 45.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.5%
EPS Next 3Y45.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (5/2/2025, 8:08:50 PM)

After market: 315.48 0 (0%)

315.48

-12.22 (-3.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners96.65%
Inst Owner Change0.02%
Ins Owners5.45%
Ins Owner Change5.89%
Market Cap7.00B
Analysts82.73
Price Target422.35 (33.88%)
Short Float %20.01%
Short Ratio10.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.86%
Min EPS beat(2)7.5%
Max EPS beat(2)30.22%
EPS beat(4)2
Avg EPS beat(4)4.3%
Min EPS beat(4)-15.12%
Max EPS beat(4)30.22%
EPS beat(8)3
Avg EPS beat(8)2.42%
EPS beat(12)5
Avg EPS beat(12)0.91%
EPS beat(16)8
Avg EPS beat(16)2%
Revenue beat(2)2
Avg Revenue beat(2)172.99%
Min Revenue beat(2)78.29%
Max Revenue beat(2)267.7%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.84%
PT rev (3m)11.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.15%
EPS NY rev (1m)-0.22%
EPS NY rev (3m)4.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)8.36%
Revenue NY rev (1m)4.3%
Revenue NY rev (3m)15.09%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 240.92
P/S 91.18
P/FCF N/A
P/OCF N/A
P/B 9.01
P/tB 9.07
EV/EBITDA N/A
EPS(TTM)-18.05
EYN/A
EPS(NY)1.31
Fwd EY0.42%
FCF(TTM)-19.74
FCFYN/A
OCF(TTM)-19.42
OCFYN/A
SpS3.46
BVpS35.01
TBVpS34.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.33%
ROE -66.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 226.39%
FCFM N/A
ROA(3y)-61.5%
ROA(5y)-68.68%
ROE(3y)-101.19%
ROE(5y)-102.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.15
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 839.77%
Cap/Sales 9.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.98
Quick Ratio 5.93
Altman-Z 11.84
F-Score6
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)305.68%
Cap/Depr(5y)207.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.01%
EPS Next Y41.51%
EPS Next 2Y43.5%
EPS Next 3Y45.37%
EPS Next 5Y42.47%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year235.79%
Revenue Next 2Y142.24%
Revenue Next 3Y116.01%
Revenue Next 5Y83.57%
EBIT growth 1Y-57.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year5.63%
EBIT Next 3Y21.39%
EBIT Next 5YN/A
FCF growth 1Y-44.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.33%
OCF growth 3YN/A
OCF growth 5YN/A